Understanding the genetic basis for adverse drug effects: The calcineurin inhibitors

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 195-209

  Bai, Jane P F ^a   Lesko, Lawrence J ^a   Burckart, Gilbert J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

ADE; Adverse drug effect; Adverse drug event; Calcineurin inhibitors; Genetics; Personalized medicine

Indexed keywords

ADENOSINE 5' TRIPHOSPHATE BINDING CASSETTE 8; ADENOSINE TRIPHOSPHATE; AUTOTAXIN; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPATOCYTE NUCLEAR FACTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; NEUROSERPIN; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

CHRONIC GRAFT REJECTION; CYTOKINE PRODUCTION; DIABETES MELLITUS; FOCAL GLOMERULOSCLEROSIS; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; GRAFT REJECTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MICROARRAY ANALYSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT;

BIOMARKERS, PHARMACOLOGICAL; CALCINEURIN; CYCLOSPORINE; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; GENOTYPE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; KIDNEY FAILURE; POLYMORPHISM, GENETIC; RISK FACTORS; TACROLIMUS;

EID: 75849143794     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.195     Document Type: Review

References (73)

1. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-16.
2. 2- adrenergic receptor gene. Pharmacogenomics J 2005;5:292-7.
3. 2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins. J Intern Med 2000;247:651-6.
4. 2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin Chim Acta 2001;314:85-91.
5. Esteva-Font C, Ars E, Guillen-Gomez E, et al. Ciclosporininduced hypertension is associated with increased sodium transporter of the Loop of Henle (NKCC2). Nephrol Dial Transplant 2007;22:2810-16.
6. Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006;13:47-55.
7. Heisel O, Heisel R, Balshaw R, Keown P. New-onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95.
8. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49:310-17.
9. Gallon L, Akalin E, Lynch P, et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation 2006;81:463-8.
10. Biselli PM, Abbud-Filho M, Ferreira-Baptista MA, de Alvarenga MP, Goloni-Bertollo EM, Pavarino-Bertelli EC. Angiotensin-converting enzyme gene polymorphism in chronic allograft nephropathy. Transplant Proc 2006;38:1327-8.
11. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 2006;21:979-83.
12. Osawa N, Koya D, Araki S, et al. Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet 2007;52:143-51.
13. Babel N, Gabdrakhmanova L, Hammer MH, et al. Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease. J Nephrol 2006;19:802-7.
14. Osterholm C, Veress B, Simanaitis M, Hedner U, Ekberg H. Differential expression of tissue factor (TF) in calcineurin inhibitor - induced nephrotoxicity and rejection-implications for development of a possible diagnostic marker. Transpl Immunol 2005;15:165-72.
15. Babel N, Cherepnev G, Kowalenko A, Horstrup J, Volk HD, Reinke P. Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. Kidney Int 2004;66:428-32.
16. Buraczynska M, Ksiazek P, Kubit P, Zaluska W. Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Cytokine 2006;36:167-72.
17. 1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 2005;80:1681-5.
18. Catarsi P, Ravazzolo R, Emma F, et al. Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes. Hum Mol Genet 2005;14:2357-67.
19. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004;4:1776-85.
20. Zhang Q, Reed EF. Array-based methods for diagnosis and prevention of transplant rejection. Expert Rev Mol Diagn 2006;6:165-78.
21. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007;83:448-57.
22. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-33.
23. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004;43:953-65.
24. Gonzalez-Posada JM, Hernandez D, Bayes Genis B, Garcia Perez J, Rivero Sanchez M. Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant 2004;19(suppl 3):iii57-61.
25. Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007;22:1986-93.
26. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-6.
27. David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007;84:50-5.
28. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221-7.
29. Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005;80:1419-24.
30. Silander K, Mohlke KL, Scott LJ, et al. Genetic variation near the hepatocyte nuclear factor-4α gene predicts susceptibility to type 2 diabetes. Diabetes 2004;53:1141-9.
31. Winckler W, Graham RR, de Bakker PI, et al. Association testing of variants in the hepatocyte nuclear factor-4α gene with risk of type 2 diabetes in 7883 people. Diabetes 2005;54:886-92.
32. Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the HNF4α gene are associated with the conversion to type 2 diabetes mellitus: the STOPNIDDM trial. J Mol Med 2006;84:701-8.
33. Holmkvist J, Cervin C, Lyssenko V, et al. Common variants in HNF-1α and risk of type 2 diabetes. Diabetologia 2006;49:2882-91.
34. Winckler W, Burtt NP, Holmkvist J, et al. Association of common variation in the HNF1α gene region with risk of type 2 diabetes. Diabetes 2005;54(8):2336-42.
35. Weedon MN, Owen KR, Shields B, et al. A large-scale association analysis of common variation of the HNF1α gene with type 2 diabetes in the U.K. Caucasian population. Diabetes 2005;54:2487-91.
36. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N Engl J Med 2006;355:241-50.
37. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007;92:1502-9.
38. Abate N, Chandalia M, Satija P, et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 2005;54:1207-13.
39. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003;4:257-91.
40. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005;48:1247-57.
41. Hitman GA, Mannan N, McDermott MF, et al. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998;47:688-90.
42. Ramos-Lopez E, Jansen T, Ivaskevicius V, et al. Protection from type 1 diabetes by vitamin D receptor haplotypes. Ann N Y Acad Sci 2006;1079:327-34.
43. Kulkarni RN, Kahn CR. Molecular biology. HNFs - linking the liver and pancreatic islets in diabetes. Science 2004;303:1311-12.
44. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004;303:1378-81.
45. Gupta RK, Kaestner KH. HNF-4α: from MODY to late-onset type 2 diabetes. Trends Mol Med 2004;10:521-4.
46. Yamamoto K, Burckart GJ, Min D, et al. Genetic risk factors for new-onset diabetes mellitus in immunosuppressed renal transplant recipients [abstract]. J Clin Pharmacol 2006;46:1088.
47. Florez JC. The new type 2 diabetes gene TCF7L2. Curr Opin Clin Nutr Metab Care 2007;10:391-6.
48. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-3.
49. Riedel MJ, Steckley DC, Light PE. Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. Hum Genet 2005;116:133-45.
50. Nielsen EM, Hansen L, Carstensen B, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003;52:573-7.
51. Sperling MA. ATP-sensitive potassium channels: neonatal diabetes mellitus and beyond. N Engl J Med 2006;355:507-10.
52. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetesassociated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the diabetes prevention program. Diabetes 2007;56:531-6.
53. Laukkanen O, Pihlajamaki J, Lindstrom J, et al . Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish diabetes prevention study. J Clin Endocrinol Metab 2004;89:6286-90.
54. Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor α-subunit. Diabetes 2000;49:13-19.
55. Stolerman ES, Manning AK, McAteer JB, et al. Haplotype structure of the ENPP1 gene and nominal association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham heart study. Diabetes 2008;57:1971-7.
56. Genctoy G, Kahraman S, Arici M, et al. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation. Transplant Proc 2006;38:521-8.
57. Stephens JW, Dhamrait SS, Cooper JA, et al. The D allele of the ACE I/D common gene variant is associated with type 2 diabetes mellitus in Caucasian subjects. Mol Genet Metab 2005;84:83-9.
58. Hess AM, Sullivan DL. Metformin for prevention of type 2 diabetes. Ann Pharmacother 2004;38:1283-5.
59. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus. Drugs 2005;65:1-13.
60. Andoh TF, Johnson RJ, Lam T, Bennett WM. Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. Am J Transplant 2001;1:222-7.
61. Flatman PW. Cotransporters, WNKs and hypertension: important leads from the study of monogenetic disorders of blood pressure regulation. Clin Sci (Lond) 2007;112:203-16.
62. 2+ exchanger expression. Ann N Y Acad Sci 2007;1099:204-14.
63. Biller H, Zissel G, Ruprecht B, Nauck M, Busse Grawitz A, Muller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J 2006;28:1085-90.
64. Basset EA, Berthoux P, Cecillon S, et al. Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS. Clin Nephrol 2002;57:192-200.
65. Serdaroglu E, Mir S, Berdeli A. Hypertension and ACE gene insertion/deletion polymorphism in pediatric renal transplant patients. Pediatr Transplant 2005;9:612-17.
66. Miyamoto Y, Saito Y, Kajiyama N, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998;32:3-8.
67. Moe KT, Lim ST, Wong P, et al. Association analysis of endothelial nitric oxide synthase gene polymorphism with primary hypertension in a Singapore population. J Hum Hypertens 2006;20:956-63.
68. Olcay A, Ekmekci CG, Ozbek U, et al. Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients: effect of ecNOS polymorphism on left ventricular hypertrophy [online exclusive article]. Cardiovasc Ultrasound 2006;4:33. Available from http://www.cardiovascularultrasound.com/content/4/1/33.
69. Calo LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor - induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002;40:625-31.
70. Calo L, Semplicini A, Davis PA, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transpl Int 2000;13(suppl 1):S413-18.
71. Ho H, Pinto A, Hall SD, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005;45:294-8.
72. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 2004;29:11-17.
73. Konrad T, Lubben G, Franzen C. Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus: an open, multicentre, observational study. Clin Drug Investig 2005;25:337-40.